TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

Benzinga Logo Benzinga By Vandana Singh
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

Merck reported positive Phase 2 CADENCE study results for Winrevair in treating combined pulmonary hypertension, showing significant reduction in pulmonary vascular resistance and a consistent safety profile.

Insights
NVDA   neutral

Mentioned as a key competitor to AMD, previously outperformed AMD but now seeing slower growth


MRK   positive

Demonstrated promising clinical trial results for Winrevair, met primary study endpoint, planning Phase 3 development, and stock price increased by 4.70%